Evidence map›Paper›PMID 27257133›Full record

ArticleJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer2016

Heterogeneity of EGFR Aberrations and Correlation with Histological Structures: Analyses of Therapy-Naive Isogenic Lung Cancer Lesions with EGFR Mutation.

Kenichi Suda, Isao Murakami, Hui Yu, Kim Ellison, Masaki Shimoji, Carlo Genova, Christopher J Rivard, Tetsuya Mitsudomi, Fred R Hirsch

Abstract readCase Reports
In one paragraph

Article in Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. A case of differentJournal of thoracic disease · 2018
    Article
  5. Primary Double-Strike Therapy for Cancers to Overcome EGFR Kinase Inhibitor Resistance: Proposal from the Bench.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Kenichi SudaDivision of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, Colorado; Division of Thoracic Surgery, Department of Surgery, Faculty of Medicine, Kindai University, Osakasayama, Japan.
Isao MurakamiDepartment of Respiratory Medicine, Higashihiroshima Medical Center, Higashihiroshima, Japan.
Hui YuDivision of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
Kim EllisonDivision of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
Masaki ShimojiDivision of Thoracic Surgery, Department of Surgery, Faculty of Medicine, Kindai University, Osakasayama, Japan.
Carlo GenovaDivision of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
Christopher J RivardDivision of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
Tetsuya MitsudomiDivision of Thoracic Surgery, Department of Surgery, Faculty of Medicine, Kindai University, Osakasayama, Japan.
Fred R HirschDivision of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, Colorado. Electronic address: fred.hirsch@ucdenver.edu.

Funding

University of Colorado Cancer Center Support Grant - Lung Cancer Patient-Derived Xenografts with Autologous Human Immune SystemsP30CA046934 · NCI · UNIVERSITY OF COLORADO DENVER · PI James V Degregori · 1988 to 2026
$117.0M
Tissue Bank and Biomarkers CoreP50CA058187 · NCI · UNIVERSITY OF COLORADO DENVER · PI MILLER, YORK E · 1992 to 2018
$43.8M
NCI NIH HHS P30 CA046934NCI NIH HHS P50 CA058187
6 · The paper itself

Abstract

introductionEGFR gene somatic mutation is reportedly homogeneous. However, there are few data regarding the heterogeneity of expression of mutant EGFR protein and EGFR gene copy number, especially in extrathoracic lesions. These types of data may enhance our understanding of the biology of EGFR-mutated lung cancer and our understanding of the heterogeneous response patterns to EGFR TKIs.

methodsAn 81-year-old never-smoking female with lung adenocarcinoma could not receive any systemic therapy because of her poor performance status. After her death, 15 tumor specimens from different sites were obtained by autopsy. Expression of mutant EGFR protein and EGFR gene copy numbers were assessed by immunohistochemical analysis and by silver in situ hybridization, respectively. Heterogeneity in these EGFR aberrations was compared between metastatic sites (distant versus lymph node) or histological structures (micropapillary versus nonmicropapillary).

resultsAll lesions showed positive staining for mutant EGFR protein, except for 40% of the papillary component in one of the pulmonary metastases (weak staining below the 1+ threshold). Expression of mutant-specific EGFR protein, evaluated by H-score, was significantly higher in the micropapillary components than in the nonmicropapillary components (Mann-Whitney U test, p = 0.014). EGFR gene copy number was quite different between lesions but not correlated with histological structure or metastatic form. However, EGFR gene copy numbers were similar between histological structures in each lesion.

conclusionThese data indicate that expression of EGFR mutant protein and EGFR gene copy number do not change as a consequence of tumor progression. This also justifies using the biopsy specimens from metastases as a surrogate for primary tumors.

Indexed as

AdenocarcinomaAdenocarcinoma of LungAged, 80 and overErbB ReceptorsFemaleHumansLung NeoplasmsMutationErbB ReceptorsAutopsyLung adenocarcinomaMicropapillaryMutant-specific antibodySilver in situ hybridization

Identifiers

PMID27257133
PMCPMC5327856

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.